Background During laparoscopic cholecystectomy, common bile duct (CBD) injury is a rare but severe complication. To reduce the risk of injury, near-infrared (NIR) fluorescent cholangiography using indocyanine green (ICG) has recently been introduced as a novel method of visualizing the biliary system during surgery. To date, several studies have shown feasibility of this technique; however, liver background fluorescence remains a major problem during fluorescent cholangiography. The aim of the current study was to optimize ICG dose and timing for NIR cholangiography using a quantitative intraoperative camera system during open hepatopancreatobiliary (HPB) surgery. Subsequently, these results were validated during laparoscopic cholecystectomy using a laparoscopic fluorescence imaging system. Methods Twenty-seven patients who underwent NIR imaging using the Mini-FLARE image-guided surgery system during open HPB surgery were analyzed to assess optimal dosage and timing of ICG administration. ICG was intravenously injected preoperatively at doses of 5, 10, and 20 mg, and imaged at either 30 min (early) or 24 h (delayed) post-injection. Next, the optimal doses found for early and delayed imaging were applied to two groups of seven patients (n = 14) undergoing laparoscopic NIR fluorescent cholangiography during laparoscopic cholecystectomy. Results Median liver-to-background contrast was 23.5 (range 22.1-35.0), 16.8 (range 11.3-25.1), 1.3 (range 0.7-7.8), and 2.5 (range 1.3-3.6) for 5 mg/30 min, 10 mg/ 30 min, 10 mg/24 h, and 20 mg/24 h, respectively. Fluorescence intensity of the liver was significantly lower in the 10 mg delayed-imaging dose group compared with the early imaging 5 and 10 mg dose groups (p = 0.001), which resulted in a significant increase in CBD-to-liver contrast ratio compared with the early administration groups (p \ 0.002). These findings were qualitatively confirmed during laparoscopic cholecystectomy. Conclusion This study shows that a prolonged interval between ICG administration and surgery permits optimal NIR cholangiography with minimal liver background fluorescence.
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Keywords Near-infrared fluorescence imaging Á Image-guided surgery Á Intraoperative cholangiography Á Indocyanine green Á Laparoscopic cholecystectomy Laparoscopic cholecystectomy is the most frequently performed abdominal surgical procedure, and one of the most common operations in Europe and the US [1, 2] . Surgical morbidity has been reported as 2-4 %; however, the incidence of major complications that require acute re-intervention is much lower [3] . A rare but serious complication of laparoscopic cholecystectomy is bile duct injury (BDI), with a reported incidence of 0.3-1.5 % [4, 5] . BDI is a feared surgical complication since it is associated with severe morbidity, impaired survival, and poor longterm quality of life [6] .
To reduce the risk of BDI, large retrospective and prospective studies have looked at the benefit of routine intraoperative radiographic cholangiography (IOC) for detection of common bile duct (CBD) stones and to identify or prevent BDI. Whether this procedure should be performed routinely is still an active subject of debate as systematic reviews are inconclusive [7] ; however, several of the larger retrospective studies observed a decrease in frequency and severity of BDI when IOC is performed [8] . Limiting factors for performing radiographic laparoscopic cholangiography include: (i) it requires specific expertise in the technique and its interpretation; (ii) it involves the use of ionizing radiation; (iii) it is time-consuming; and (iv) it creates a risk for bile leakage and duct injury itself, since puncturing and cannulation of the cystic duct is required. These limitations justify the quest for alternative, less complicated techniques to visualize biliary anatomy during cholecystectomy.
Recently, near-infrared (NIR) fluorescent cholangiography using indocyanine green (ICG) has been presented as a novel, less invasive, and non-ionizing method to visualize the biliary system during surgery [9] [10] [11] . Circulating ICG is cleared by the liver and almost exclusively excreted into the bile [12] . Following intravenous injection of ICG, the extrahepatic bile ducts can be clearly visualized using a laparoscopic fluorescence imaging system. The NIR fluorescence window (700-900 nm) has several advantages for image-guided surgery, such as minimal autofluorescence of the surgical field and several millimeters penetration of the fluorescent light through overlying tissue [13, 14] . In addition, as NIR light is invisible to the human eye, illumination does not alter the surgical field. In the largest series of patients published so far on the use of this technique during laparoscopic cholecystectomy, NIR fluorescent cholangiography delineated biliary anatomy in the majority of patients before dissection of Calot's triangle [9] .
Although hepatic excretion pharmacokinetics enable the use of ICG for fluorescence imaging of the extrahepatic bile ducts, at the same time, retention of ICG in the liver can cause significant background fluorescence signal that impairs discrimination of bile ducts from liver tissue. To date, studies using ICG for NIR fluorescence cholangiography have used variable doses that were injected only at timepoints directly prior to surgery [15] . We hypothesize that the excretion of ICG from the liver, and thereby the interval between intravenous ICG injection and surgery, would be one of the key determinants for optimal differentiation of bile duct signal from its surrounding tissue during fluorescence cholangiography. The aim of the current study was to compare early-and delayed-imaging protocols using different doses of ICG to optimize NIR cholangiography using a quantitative intraoperative camera system during open hepatopancreatobiliary (HPB) surgery. These results were subsequently validated during laparoscopic cholecystectomy using a laparoscopic fluorescence imaging system.
Materials and methods

Intraoperative near-infrared imaging systems
Intraoperative imaging during open surgery was performed using the Mini-Fluorescence-Assisted Resection and Exploration (Mini-FLARE) image-guided surgery system, as described previously [16] . Briefly, the system consists of two wavelength isolated light sources: a 'white' light source, generating 26,600 lx of 400-650 nm light, and an 'NIR' light source, generating 7.7 mW/cm 2 of 760 nm light. The Mini-FLARE imaging system was positioned 30 cm above the surgical field. Color video and NIR fluorescence images were simultaneously acquired and displayed in real time using custom optics and software that separate the color video and NIR fluorescence images.
Laparoscopic imaging was performed using two D-light fluorescence laparoscopes (Tricam SLII and Image 1 High Definition; Karl Storz Endoscopes, Germany) through a standard 12 mm subumbilical trocar port. In this imaging system, 760 nm light, emitted by an internal light source, is guided through a special fluid light cable to a 30°infrared-optimized rigid laparoscope containing an optical filter system. The system was used for intraoperative conventional imaging (white light mode) and real-time fluorescence imaging (760 nm light, ICG mode) and allowed easy switching between white light mode and ICG mode by using a foot pedal. No overlay of conventional and fluorescent images was possible, but anatomical orientation could be maintained due to the easy switching between light modes. Images are recorded using a charge-coupled device camera.
Preparation and administration of indocyanine green (ICG)
ICG (25 mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) and re-suspended in 10 cc of sterile water for injection to yield a 2.5 mg/mL (3.2 mM) stock solution. Of this stock solution, 2, 4, or 8 mL, corresponding to doses of 5, 10, or 20 mg, was administered intravenously as a bolus.
Patients
To assess optimal dosage and timing of ICG administration for NIR fluorescent cholangiography, patients from two HPB imaging trials for the identification of pancreatic and liver tumors [NTR2213 and NTR2214 (Netherlands Trial Registrar, Dutch Cochrane Center, Amsterdam)] were analyzed separately. All patients in which the biliary anatomy was exposed were included. This resulted in a cohort of 27 patients (Table 1) . Patients received an intravenous bolus of 5 or 10 mg of ICG in the operating room 30 min before incision (early imaging), or 10 or 20 mg at 24 h prior to surgery (delayed imaging). NIR fluorescence signal of the bile ducts and liver was quantified using the Mini-FLARE imaging system. Subsequently, to validate the findings from open surgery, a total of 14 patients planning to undergo laparoscopic cholecystectomy were included to receive the optimal doses of ICG for either early (n = 7) or delayed (n = 7) imaging. Laparoscopic images were acquired using the Tricam SLII fluorescence laparoscope or Image 1 High Definition fluorescence laparoscope. This trial has been registered as NTR3686 in the Netherlands Trial Registrar, Dutch Cochrane Center, Amsterdam. All patients provided informed consent. Exclusion criteria were pregnancy, lactation, or an allergy to iodine, shellfish, or ICG. The studies were approved by the Local Medical Ethics Committee of the Leiden University Medical Center and were performed in accordance with the ethical standards of the Helsinki Declaration of 1975.
Statistical analysis
For statistical analysis, SPSS statistical software package (Version 17.0; Chicago, IL, USA) was used. Graphs were generated using GraphPad Prism Software (Version 5.01; La Jolla, CA, USA). Signal-to-background ratios (SBR) were calculated by dividing the fluorescent signal of the CBD by fluorescent signal of surrounding adipose tissue or the liver. SBG, ratios were reported as median with range. To test differences between groups, the Kruskal-
Results
Study subjects
Patient characteristics are detailed in Table 1 . Twentyseven patients underwent open HPB surgery, of which 20 were planned for liver resection for colorectal metastases and 7 were planned for surgery with suspected ampullary or pancreatic head carcinoma. Subsequently, 14 patients who were planned for elective laparoscopic cholecystectomy for cholecystolithiasis were included to undergo laparoscopic NIR fluorescence cholangiography.
Optimization of ICG dose and administration timing
Intraoperative NIR fluorescence imaging was performed using the quantitative mini-FLARE imaging system to evaluate the effect of ICG dosage and post-injection imaging time for open surgery (Fig. 1) . The effect of the injected ICG dosage and timing on fluorescence brightness was determined by comparing median SBR between different groups (Figs. 2, 3) .
Median liver-to-background contrast was 23.5 (range 22.1-35.0), 16.8 (range 11.3-25.1), 1.3 (range 0.7-7.8), and 2.5 (range 1.3-3.6) for 5 mg/30 min, 10 mg/30 min, 10 mg/24 h, and 20 mg/24 h, respectively ( Fig. 2A) . Liver background contrast was significantly lower in the 10 mg delayed-imaging dose group compared with the early imaging 5 and 10 mg dose groups (p \ 0.001).
To assess the influence of the liver background signal, the ratio between CBD and liver signal was determined. Median SBR, expressed as CBD-to-liver ratio, were 0.2 (range 0.2-0.3), 0.2 (range 0.1-0.6), 2.3 (range 1.1-6.2), and 1.7 (range 1.6-2.9) for 5 mg/30 min, 10 mg/30 min, 10 mg/ 24 h, and 20 mg/24 h, respectively. Again, a significant ICG indocyanine green difference was found between the early imaging 5 and 10 mg dose groups and the delayed imaging 10 mg dose group (p \ 0.002) (Fig. 3 ). An example of this difference in contrast ratio is illustrated in Figs. 1 and 4 . Most importantly, when considering the ratio between the CBD and surrounding adipose tissue, no differences were found between dose groups (p = 0.47) (Fig. 2B ).
This indicates that the fluorescence intensity of the CBD itself did not differ between dose groups.
Validation during laparoscopic cholecystectomy
Subsequently, 14 patients undergoing laparoscopic cholecystectomy were included and given the optimal doses found for early (5 mg/30 min; n = 7) and delayed (10 mg/ 24 h; n = 7) imaging. The first eight patients were imaged using the Tricam SLII laparoscopic system, which has recently been reported [11] . However, brightness of the fluorescence images in both dose groups was considerably lower compared with the images obtained with the Mini-FLARE system. To decrease this shortcoming, a newly developed, next-generation Image 1 'High Definition' laparoscopic system was used in the latter six patients. The improved sensitivity of the CCD chip not only increased fluorescence brightness but also allowed better anatomical orientation in fluorescence mode. Intraoperative NIR fluorescence cholangiography permitted detection of the cystic duct in all patients. Although the laparoscopic NIR fluorescence imaging system was unable to quantify the fluorescence signal intensity, qualitative data analyses revealed a much higher liver signal in the 5 mg/30 min group compared with the 10 mg/24 h group (Fig. 4) . These results were in concordance with our quantitative findings during open surgery using the Mini-FLARE system, as can be seen in Figs. 1, 2 and 3.
Discussion
The current study demonstrates feasibility and optimization of NIR fluorescence cholangiography during both open and laparoscopic HPB surgery. To our knowledge this is the first clinical study comparing the effect on dosage and timing of ICG administration for bile duct imaging using intraoperative NIR fluorescence. However, further optimization of the technology is still necessary. ICG is cleared from blood by the liver within seconds and appears in bile within minutes [17] . The ratio of CBD to liver NIR fluorescence peaks or plateaus (depending on species) within 2-6 h. We purposely chose to test the extremes of clearance time (30 min vs. 24 h) in this clinical study; however, future studies must explore intermediate timepoints in the hope that more clinically convenient timing, e.g. in the pre-operative area for same day surgery, can be found.
NIR fluorescent light has several advantages for intraoperative imaging. For example, NIR light is invisible to the human eye, and therefore does not alter the look of the surgical field. Further advantages of NIR light include high tissue penetration (up to several millimeters) and low autofluorescence. Moreover, NIR fluorescence imaging is an inherently safe technique, as there is no ionizing radiation and no direct tissue contact, in contrast to intraoperative cholangiography or ultrasonography.
Visualization of the biliary anatomy can be challenging during laparoscopic cholecystectomy. Previous performed studies have shown feasibility of NIR fluorescence imaging for safe exploration of biliary anatomy [9, 10, [18] [19] [20] [21] [22] [23] [24] [25] . Recently, feasibility of fluorescent cholangiography has even been evaluated during robotic single-site cholecystectomy [26] ; however, optimal dosage and timing were, thus far, not investigated. After systemic injection, ICG is completely absorbed by the liver within several minutes. Subsequently, ICG is excreted in the bile, which allows NIR fluorescence visualization of the biliary anatomy. Inherent to this, liver background remains a major problem during NIR fluorescent cholangiography. This study shows that a dose of 10 mg ICG injected 24 h prior to surgery provides a significantly lower liver background signal, while the CBD signal remains stable (Figs. 2, 3) . Therefore, the contrast ratio between bile duct versus liver background is considerably higher, which allows optimal visualization of the extrahepatic bile ducts (Figs. 1, 4) . A limitation of this method is the time window of approximately 24 h that is needed between intravenous injection of the contrast agent and start of surgery. This could be a disadvantage during day-case admissions of patients for an elective laparoscopic cholecystectomy. Similarly, this time window cannot be used for patients suffering from acute cholecystitis in which early surgery is preferred. Still, in these cases we argue that administration of ICG should be performed as early as possible following admission to allow the majority of the contrast agent to be cleared from the liver before NIR fluorescent cholangiography is performed.
Currently, ICG and methylene blue are the only two NIR contrast agents that are approved for other clinical applications; however, methylene blue is not suitable for bile duct imaging due to predominantly renal clearance in humans [14] . Novel NIR contrast agents have been developed, but presently lack regulatory approval. Our group has previously compared the use of different contrast agents for NIR fluorescent cholangiography in both a small and a large preclinical animal model [17] . This study showed that IRDye 800CW provided prolonged visualization of the biliary anatomy with reduced liver background fluorescence when compared with both ICG and IR-786. A significant advantage of NIR imaging is that it can provide real-time guidance; however, to enable the surgeon to work under direct image guidance, navigation in relation to the surgical anatomy is obligatory. Further technical developments of (laparoscopic) NIR imaging systems are in progress aiming to improve the real-time intraoperative display of NIR fluorophores [27, 28] . A recently published case report of laparoscopic NIR fluorescence imaging uses a camera system that is able to overlay the fluorescence images of the biliary tract with conventional color images in real time [29] . Moreover, this case report also clearly shows the issue of liver background fluorescence when using ICG injected shortly before surgery.
Conclusion
The current study demonstrates feasibility of NIR fluorescent cholangiography for both open and laparoscopic surgery. Until novel NIR contrast agents become available for clinical use, only ICG can be applied for this purpose. A dosage of 10 mg administered 24 h before surgery appears to produce optimal results for NIR fluorescent cholangiography during both open and laparoscopic surgery. When permitted by logistics, we would recommend using a prolonged interval between ICG administration and intraoperative bile duct imaging.
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